Latest news with #LemonaidHealth
Yahoo
7 days ago
- Business
- Yahoo
Here's how to file a claim amid 23andMe bankruptcy
KANSAS CITY, Mo. — Missouri Attorney General Andrew Bailey is alerting consumers that 23andMe, Lemonaid Health, Telehealth and Pharmacy filed for bankruptcy on March 23, 2025. If you believe any one of these businesses owes you money or if you believe you may have any other type of claim against them, Bailey said you must file a proof of claim. Download WDAF+ for Roku, Fire TV, Apple TV Who should file a claim Anyone who believes that 23andMe, Lemonaid Health, Telehealth, or Pharmacy owes them money, or if you believe you have any other type of claim against them, you should file a general proof of claim form, which can be found here: Data breach victims If you are a victim of the 2023 23andMe data breach, you should file a special proof of claim form, which can be found here: The deadline to file a claim is July 14, to file Electronically – Consumers may file their claim electronically through the official Kroll website. Instructions and more information about the bankruptcy is available here: First Class U.S. Mail – Consumers may mail a proof of claim to the address below. If a proof of claim is mailed, it must arrive by 4:59 PM CT on July 14, 2025. U.S. Mailing Address: 23andMe Holding Co. Claims Processing Center c/o Kroll Restructuring Administration LLC Grand Central Station, PO Box 4850 New York, NY 10163-4850 Hand Delivery or Overnight Courier: Consumers may deliver a proof of claim to the address below. If a proof of claim is delivered, it must arrive by 4:59 PM CT on July 14, 2025. Address: 23andMe Holding Co. Claims Processing Center c/o Kroll Restructuring Administration LLC 850 3rd Avenue, Suite 412 Brooklyn, NY 11232 Consider deleting your data In addition to filing a claim in the bankruptcy, Bailey said consumers may wish to delete their 23andMe account if they want their personal data erased from the 23andMe system. Otherwise, their personal genetic data and genetic material could be sold as an asset in the bankruptcy case. Consumers with a 23andMe account can delete their account, personal genetic data, and genetic material by following the steps below. How to delete genetic data from 23andMe Log into your 23andMe account. Go to the 'Settings' section of your profile. Scroll down to a section labeled '23andMe Data' at the bottom of the page. Click 'View' next to '23andMe Data.' Download your data if you'd want to retain a copy of your genetic data for personal storage. Scroll down to the 'Delete Data' section. Click 'Permanently Delete Data.' Confirm your request by following the instructions emailed to you by 23andMe. You must confirm the request to have your data removed. How to destroy your 23andMe test sample If you previously opted to have your saliva sample and DNA stored by 23andMe, but want to change that preference, you can do so from your account settings page, under 'Preferences.' How to revoke permission for your genetic data to be used for research If you previously consented to 23andMe and third-party researchers to use your genetic data and sample for research, you may withdraw consent from the account settings page under 'Research and Product Consents.' Additional information on the account deletion process can be found online here. Case Information On March 23, 2025, the genetic testing and information company, 23andMe, and affiliated entities ('the company') filed for Chapter 11 bankruptcy in the United States Bankruptcy Court for the Eastern District of Missouri. The company has proposed to sell all of its assets by June 17, 2025. Bailey said consumers' genetic data may be considered an asset that could be sold to a potential buyer in the bankruptcy process. In support of Missouri consumers, the Missouri Attorney General sought the appointment of an independent consumer protection ombudsman. The bankruptcy court granted the request, and privacy expert Professor Neil Richards has been selected. He will evaluate whether the company can legally sell its customers' data, including their genetic material. He will consider the relevant state and federal laws, as well as the customers' agreements and representations to customers, and then issue a report to the bankruptcy court. Currently, customers can still delete their data. As outlined in the 'Frequently Asked Questions' page on the 23andMe bankruptcy administration website, 'Customers still have the ability to delete their data and 23andMe account.'Missouri consumers who have been impacted by the bankruptcy of 23andMe may submit a complaint at or call the Consumer Protection Hotline at 800-392-8222. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Time of India
20-05-2025
- Business
- Time of India
Bankrupt DNA testing company 23andMe to be acquired by Regeneron for $256 million
Regeneron Pharmaceuticals has announced it will acquire 23andMe, the once high-flying consumer DNA testing company , for $256 million through a bankruptcy auction. The deal comes after 23andMe filed for Chapter 11 bankruptcy protection in March amid plummeting demand for its ancestry kits and fallout from a 2023 data breach. Tired of too many ads? go ad free now Regeneron, a major player in biotech and pharmaceuticals, said it will honor 23andMe's privacy commitments and adhere to legal safeguards around customer genetic data. The acquisition raises questions about how the vast trove of personal health information from 15 million users will now be handled. Why 23andMe went bankrupt Once a pioneer in the consumer DNA testing market, 23andMe faced a steady decline in demand as public interest in ancestry testing waned. The situation worsened after a 2023 data breach compromised the genetic data of millions of customers, damaging the company's credibility and triggering lawsuits. At the same time, the firm struggled to pivot to new business models, including health insights and telemedicine, which failed to generate sufficient revenue. Mounting losses and limited investor confidence ultimately pushed the company to seek bankruptcy protection. Privacy concerns draw scrutiny Regeneron said it will comply with 23andMe's privacy policies and relevant laws when handling customer data. A court-appointed overseer will monitor the company's data use, a safeguard agreed upon in April amid fears that sensitive genetic profiles could fall into the wrong hands. Lawmakers and privacy advocates had raised alarms when 23andMe first entered bankruptcy, warning that consumer data must be protected even in the course of a sale. Tired of too many ads? go ad free now Data breach and business decline The sale marks a significant turn for 23andMe, which was once among the leading personal genomics companies. However, demand for at-home DNA testing declined sharply in recent years, and the company's reputation took a hit after a major 2023 data breach exposed the personal data of millions. The incident led to lawsuits and further eroded public trust, contributing to its financial troubles. Exclusion of Lemonaid Health As part of the acquisition deal, Regeneron will take control of all 23andMe units except for Lemonaid Health, its telehealth subsidiary. 23andMe plans to shut down Lemonaid Health as part of its restructuring. The core genetic testing business, however, will continue operating as a wholly owned unit under Regeneron. What happens next The companies expect to close the transaction by the third quarter of 2025. Once completed, 23andMe will function as either a direct or indirect subsidiary of Regeneron. While Regeneron's specific plans for the data and technology are not yet clear, the company says it is committed to transparency and legal compliance, especially as it navigates public and regulatory scrutiny over the future of consumer genetic information .
Yahoo
19-05-2025
- Business
- Yahoo
Regeneron buys bankrupt 23andMe for $256m
23andMe has found itself a buyer after biotech Regeneron won an auction to buy the bankrupt genetics company for $256m. As part of a court-supervised sale, the auction will see Regeneron acquire the majority of 23andMe's assets. This includes the company's Personal Genome Service (PGS) and Total Health and Research Services business lines, but not the Lemonaid Health subsidiary. Lemonaid Health, a telehealth company, will be wound down by 23andMe separately. Although Regeneron and 23andMe have agreed to the $256m deal, a court hearing set for 17 June will still be required to approve the sale. The transaction is expected to close in Q3 2025 if all goes to plan. Reaction on Wall Street was tepid, with shares in Regeneron opening 1% down at market open following the announcement. The company has a market cap of $64bn. A pioneer in genetic heritage services, 23andMe saw its share price decimated in the past year as it struggled to find a sustainable business model. Once occupying a market cap of $6bn, the company diversified beyond DNA testing and started a drug research business along with more specific diagnostic insights for customers. Despite helping to transform the consumer genomics space, the company has never reported a net profit. 23andMe co-founder Anne Wojcicki tried multiple times to take the company private. Despite her push for a buyout, the company's board continually rebuffed all attempts. She eventually resigned in March 2025, the same month the company filed for bankruptcy. The future of the company has been a hot topic of conversation, largely due to the vast amount of genetic data it holds. The company has collected this from the 15 million customers who ordered its DNA testing kits online and provided saliva samples. There was a significant data breach in 2023 that affected around half of its customers - an attack from which 23andMe never fully recovered. Regeneron, perhaps best known as the maker of the blockbuster autoimmune drug Dupixent (dupilumab), still sees a future for 23andMe's service. The pharma company said it plans to 'continue all consumer genome services uninterrupted'. 23andMe will be operated as a wholly owned subsidiary of Regeneron Pharmaceuticals, with employment offered to all individuals in the acquired business units. Regeneron's chief scientific officer George Yancopoulos said: "We believe we can help 23andMe deliver and build upon its mission to help those interested in learning about their own DNA and how to improve their personal health, while furthering Regeneron's efforts to use large-scale genetics research to improve the way society treats and prevents illness overall." Regeneron has reassured customers that it will adhere to 23andMe's consumer privacy policies and data laws. Regeneron senior vice president and Regeneron Genetics Center head Aris Baras said: "We assure 23andMe customers that we are committed to protecting the 23andMe dataset with our high standards of data privacy, security and ethical oversight and will advance its full potential to improve human health." "Regeneron buys bankrupt 23andMe for $256m" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
BBC News
19-05-2025
- Business
- BBC News
Struggling DNA testing firm 23andMe to be bought for $256m
The DNA testing firm 23andMe says it has entered into an agreement to be acquired by Regeneron Pharmaceuticals for $256m (£192m).It comes two months after the company filed for bankruptcy protection in the US.23andMe said Regeneron had committed to comply with its privacy policies as part of the deal, and that Regeneron has security controls in place to protect user month, the firm agreed to have an ombudsman oversee the protection of user data in response to demands by several state attorneys general in the officials expressed concern over the potential for unscrupulous buyers to wield the data against consumers. Regeneron will acquire nearly all of 23andMe's assets, the company said in a subsidiary Lemonaid Health will be wound down under the agreement.23andMe will continue to operate as a wholly-owned unit unit of Regeneron, which said it would use the firm's data for drug development."We are pleased to have reached a transaction that maximizes the value of the business and enables the mission of 23andMe to live on, while maintaining critical protections around customer privacy, choice and consent with respect to their genetic data," said 23andMe's board chairman Mark company declined to comment further when approached by the BBC. A company's struggles 23andMe was co-founded in 2006 by Anne Wojcicki who served as CEO until stepping down in the years, the company received high-profile endorsements from celebrities including Oprah Winfrey, Eva Longoria and Snoop Dogg.23andMe went public in 2021, which saw its value top $6bn - but it never turned a once-celebrated company has struggled amid weak demand for its testing kits and never managed to redefine its business model.A subscription service failed to gain traction with customers and efforts to use its massive trove of data to move into drug development also in 2023 the company experienced a data breach that exposed the genetic data of millions of firm ultimately settled a lawsuit alleging it failed to protect the privacy of nearly seven million customers whose personal information was gained access to family trees, birth years and geographic locations, by using customers' old passwords, but the company maintains the data stolen did not include DNA months after the settlement, it slashed 200 jobs - about 40% of its Wojcicki tried to take the company private but was not open to a third-party takeover. Legacy of Data When 23andMe filed for bankruptcy protection in March, attorneys general from multiple US states advised its customers to purge their information from the firm's the time, the company said it would continue to protect customer data as laid out in its privacy policy, and any buyer of the company would have to abide by laws that apply to how customer data is its privacy policy also included language which allowed for personal information to be accessed, sold, or transferred if it was "involved in a bankruptcy, merger, acquisition, reorganization, or sale of assets".23andMe agreed to a court-appointed overseer of customer genetic data after several states alleged the company was failing to take data security seriously enough. Sign up for our Tech Decoded newsletter to follow the world's top tech stories and trends. Outside the UK? Sign up here.
CNN
19-05-2025
- Business
- CNN
Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe's privacy policies and applicable laws with respect to the use of customer data and that it is ready to detail its intended use of the data to a court-appointed overseer. The bankruptcy proceedings, filed in March, had drawn scrutiny from lawmakers who warned that millions of customers' genetic data could be sold to unscrupulous buyers. 23andMe last month agreed to allow a court-appointed overseer for the company's handling of customers' genetic information and its security policies during the bankruptcy. The company has collected genetic data from 15 million customers who ordered its DNA testing kits online and provided saliva samples. The company had been struggling with weak demand for its ancestry testing kits and a data breach in 2023 that exposed millions of customers' genetic data. As part of the agreement, Regeneron will acquire all units of 23andMe, except telehealth service Lemonaid Health, which the genetic testing firm plans to wind down. After the transaction completes, 23andMe will continue to operate as a wholly owned direct or indirect unit of Regeneron, the companies said. The companies expect to close the deal in the third quarter. See Full Web Article
